U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C7H14NO5P
Molecular Weight 223.1635
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELFOTEL, (+)-

SMILES

OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1

InChI

InChIKey=LPMRCCNDNGONCD-RITPCOANSA-N
InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1

HIDE SMILES / InChI
(+)-selfotel ((+)-CGS-19755) is an enantiomer of selfotel, a competitive antagonist at N-methyl-D-aspartate (NMDA)-preferring receptors. The inhibition of NMDA-evoked ACh release from rat striatal slices is stereospecific, with the (+)-enantiomer less potent than the (-)-enantiomer.

CNS Activity

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20676 ng/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
31622 ng × h/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Other AEs: Agitation, Confusion...
Other AEs:
Agitation (66.7%)
Confusion (50%)
Delirium (33.3%)
Paranoid reaction (50%)
Coordination abnormal (16.7%)
Aphasia (16.7%)
Hallucination (50%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Aphasia 16.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Coordination abnormal 16.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Delirium 33.3%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Confusion 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Hallucination 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Paranoid reaction 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Agitation 66.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Glutamatergic antagonism: effects on lidocaine-induced seizures in the rat.
1994 Oct
The 26th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Tromso, Norway, 13-17 June 2001.
2001 Aug
A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke.
2001 Feb 23
Regional distribution and pharmacological characteristics of [3H]N-acetyl-aspartyl-glutamate (NAAG) binding sites in rat brain.
2001 Jan
Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog.
2001 Nov 16
Neuroprotective effects of N-methyl-D-aspartate receptor antagonist on aspartate induced neurotoxicity in the spinal cord in vivo.
2003 Oct
Lessons from epidemiologic studies in clinical trials of traumatic brain injury.
2004
Nicotine exerts a permissive role on NMDA receptor function in hippocampal noradrenergic terminals.
2004 Jul
The rise and fall of NMDA antagonists for ischemic stroke.
2004 Mar
Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels.
2004 Oct
Acute nociceptive somatic stimulus sensitizes neurones in the spinal cord to colonic distension in the rat.
2004 Oct 1
Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity.
2005 Jun
The NMDA receptor complex: a long and winding road to therapeutics.
2005 Mar
Severe brain injury ICU outcomes are associated with Cranial-Arterial Pressure Index and noninvasive Bispectral Index and transcranial oxygen saturation: a prospective, preliminary study.
2006
Some prognostic models for traumatic brain injury were not valid.
2006 Feb
Risks associated with magnetic resonance imaging and cervical collar in comatose, blunt trauma patients with negative comprehensive cervical spine computed tomography and no apparent spinal deficit.
2008
NMDA-mediated modulation of dopamine release is modified in rat prefrontal cortex and nucleus accumbens after chronic nicotine treatment.
2009 Jan
Cerebral vasospasm following traumatic subarachnoid hemorrhage.
2009 Nov
Patents

Patents

Sample Use Guides

Two pivotal phase 3 ischemic stroke trials tested the hypothesis, by double-blind, randomized, placebo-controlled parallel design, that a single intravenous 1.5 mg/kg dose of Selfotel, administered within 6 hours of stroke onset, would improve functional outcome at 90 days, defined as the proportion of patients achieving a Barthel Index score of >/=60. The trials were performed in patients aged 40 to 85 years with acute ischemic hemispheric stroke and a motor deficit.
Route of Administration: Intravenous
In Vitro Use Guide
Selfotel (CGS 19755 [cis-4-phosphonomethyl-2-piperidine carboxylic acid]) was found to be a potent, stereospecific inhibitor of N-methyl-D-aspartate (NMDA)-evoked, but not KCl-evoked, [3H] acetylcholine release from slices of the rat striatum. The concentration-response curve to NMDA was shifted to the right by CGS 19755 (pA2 = 5.94), suggesting a competitive interaction with NMDA-type receptors.
Name Type Language
SELFOTEL, (+)-
Common Name English
CGS-20282
Code English
2-PIPERIDINECARBOXYLIC ACID, 4-(PHOSPHONOMETHYL)-, (2S,4R)-
Systematic Name English
(2S,4R)-4-(PHOSPHONOMETHYL)-2-PIPERIDINECARBOXYLIC ACID
Common Name English
Code System Code Type Description
FDA UNII
N0905W44Y3
Created by admin on Sat Dec 16 08:22:50 GMT 2023 , Edited by admin on Sat Dec 16 08:22:50 GMT 2023
PRIMARY
CAS
113229-62-2
Created by admin on Sat Dec 16 08:22:50 GMT 2023 , Edited by admin on Sat Dec 16 08:22:50 GMT 2023
PRIMARY
PUBCHEM
68736
Created by admin on Sat Dec 16 08:22:50 GMT 2023 , Edited by admin on Sat Dec 16 08:22:50 GMT 2023
PRIMARY